{
    "clinical_study": {
        "@rank": "97394", 
        "acronym": "msm", 
        "arm_group": [
            {
                "arm_group_label": "MSM group", 
                "arm_group_type": "Experimental", 
                "description": "Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 3 gr twice a day for 26 weeks (6 gr/day total)"
            }
        ], 
        "brief_summary": {
            "textblock": "To delineate the effect of MSM on osteoarthritis"
        }, 
        "brief_title": "Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "detailed_description": {
            "textblock": "Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design:\n      Randomized, double-blind, placebo-controlled trial including an intervention and a placebo\n      group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups.\n      Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and\n      placebo for the other. Outcomes measured are the Western Ontario and McMaster University\n      Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and\n      SF-36 (overall health-related quality of life)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Knee and hip OA\n\n          -  men and women >45 years of age\n\n        Exclusion Criteria:\n\n          -  any other type of arthritis\n\n          -  chronic pain syndrome\n\n          -  arthroscopic surgery in the past 8 months\n\n          -  intra-articular corticosteroidsin the past 8 months\n\n          -  hyaluronic acid injections in the past 8 months\n\n          -  narcotic pain killers use\n\n          -  renal or hepatic disease\n\n          -  body mass index (BMI) >45 kg/m2\n\n          -  cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836757", 
            "org_study_id": "msm2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSM group", 
                "description": "Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)", 
                "intervention_name": "MethylSulfonylMethane  (MSM)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dimethyl sulfone", 
                "Dimethyl Sulfoxide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "osteoarthritis", 
            "CAM treatments", 
            "MSM"
        ], 
        "lastchanged_date": "April 17, 2013", 
        "location": {
            "contact": {
                "last_name": "Panagiotis Givisis, MD, PhD", 
                "phone": "00306945264010"
            }, 
            "facility": {
                "address": {
                    "city": "Thessaloniki", 
                    "country": "Greece", 
                    "zip": "57010"
                }, 
                "name": "G. Papanikolaou Hospital"
            }, 
            "investigator": {
                "last_name": "Thomas Pagonis, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte", 
        "overall_contact": {
            "email": "iatros1@yahoo.com", 
            "last_name": "Thomas Pagonis, MD, PhD", 
            "phone": "00306980488686"
        }, 
        "overall_official": {
            "affiliation": "Aristotle's University of Thessaloniki", 
            "last_name": "Thomas Pagonis, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Greece: National Drug Organization", 
                "Greece: Ellinikos Organismos Farmakon EOF"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)", 
            "measure": "Number of participants with improved Mobility", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836757"
        }, 
        "responsible_party": {
            "investigator_affiliation": "G.Papanikolaou Research Group", 
            "investigator_full_name": "Thomas Pagonis", 
            "investigator_title": "Orthopaedic Surgeon", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)", 
            "measure": "Pain Scores on the Visual Analog Scale", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "source": "G.Papanikolaou Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "G.Papanikolaou Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}